February 22, 2018 10:07 AM ET

Biotechnology

Company Overview of Vaximm AG

Company Overview

Vaximm AG, a biotech company, develops active-angiogenic immunotherapies (vaccines) for the patients suffering from cancer. The company develops VXM01, an oral T-cell vaccine that is used for the treatment of cancer. Its vaccine is designed to stimulate the patients' immune system to fight the tumor vasculature, which is essential for tumors to grow beyond microscopic size. The company was founded in 2008 and is based in Basel, Switzerland. It has a subsidiary in Mannheim, Germany.

Elisabethenstrasse 3

Basel,  4051

Switzerland

Founded in 2008

Key Executives for Vaximm AG

Chief Executive Officer
Chief Medical Officer
Age: 66
Project Manager and General Manager of Vaximm GmbH
Director
Age: 60
Compensation as of Fiscal Year 2017.

Vaximm AG Key Developments

VAXIMM AG Announces Preclinical Results with Novel Oral T Cell Cancer Immunotherapies

VAXIMM AG announced that preclinical data with its oral T-cell immunotherapy platform, including one preclinical development candidate, VXM10, are being presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications" being held October 26-30, 2017 in Philadelphia, PA, USA. The poster will be presented during Poster Session B in session category "Tumor Immunology Targets" on October 29, in Hall E. The abstracts are available here. The poster, Live attenuated oral Salmonella platform for effective targeting of multiple tumor-associated epitopes and PD-L1, summarizes the immunogenicity and anti-leukemia activity of VXM10, transformed with a eukaryotic expression plasmid encoding the murine programmed death-ligand 1 (PD-L1) protein in an animal model. Multiple oral administrations of VXM10m were generally well tolerated, and no toxicity nor body weight loss were observed. Oral administration of VXM10 produced a strong anti-tumor effect in the FBL-3 leukemia model, with a 100% survival rate 80 days after leukemia challenge in those groups given the highest doses. All long-term surviving mice resisted a re-challenge with FBL-3 cells, demonstrating that vaccination with VXM10m generated a potent memory T-cell response against the leukemia cells. Importantly, full leukemia control was achieved in both prophylactic and therapeutic settings. Additionally, various polyepitope vaccines encoding dominant epitopes from VEGFR2, Mesothelin, WT1, CEA, and Ovalbumin, induced a significant systemic immunogenicity for up to 6 of 9 epitopes, 10 days after vaccination of healthy mice via the oral route. This study provides further evidence that VAXIMM's oral T-cell vaccination platform can not only be employed to stimulate anti-tumor immunity against the antigen of the immune checkpoint regulatory protein PD-L1, but also against T-cell epitopes encoded by polyepitope constructs. These data pave the way for advancing the development of VXM10 and neoantigen-based vaccines into clinical development.

Vaximm AG Presents at Sachs Associates 17th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-26-2017 through Sep-27-2017

Vaximm AG Presents at Sachs Associates 17th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-26-2017 through Sep-27-2017. Venue: The Congress Center, Basel, Switzerland. Presentation Date & Speakers: Sep-27-2017, Heinz Lubenau, Project Manager and General Manager of Vaximm GmbH.

VAXIMM Receives Orphan Designation for the European Union and the US for Oral T-cell Immunotherapy VXM01 to Treat Glioma

VAXIMM AG announced that the Company's lead product candidate, VXM01, has received orphan designation from the European Commission and from the US Food and Drug Administration (FDA) for the treatment of glioma, a difficult-to-treat form of brain cancer. Orphan designation is designed to encourage the development of drugs to treat rare diseases and conditions and provides companies with certain incentives, including periods of market exclusivity upon approval, as well as user fee reductions or exemptions. The designation by the European Commission is for the treatment of glioma and by the US FDA for the treatment of malignant glioma. Phase I results in glioblastoma, a type of glioma, were presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting on June 5, 2017. The trial was designed to evaluate the safety and tolerability of, as well as clinical and immunogenic response to, VXM01 in patients with recurrent glioblastoma whose disease had progressed following treatment with at least radiochemotherapy including temozolomide, the standard of care. The reported data were from eight patients who were given a single dose of VXM01 on days 1, 3, 5 and 7 before planned surgery on day 35. Following surgery, patients could then receive a single administration every four weeks during the follow-up period. Median dosage was seven vaccinations. Surgery was performed on seven of the treated patients. One patient experienced an objective and durable response, and three other patients had stable disease. Additionally, peripheral immune responses were observed, and five of seven patients had an increase in CD8+ T-cells in tumor tissue following re-operation compared to the primary tumor tissue. Four out of eight patients showed a specific T-cell response. In addition, in four patients a relevant increase in cerebral blood volume and apparent diffusion coefficient on post-vaccination MRI was observed. VXM01 was shown to be well tolerated. The European Medicines Agency (EMA) examines the applications for orphan designation in the European Union and facilitates the development and authorization of medicines for rare diseases. The European Commission is responsible for granting orphan designation, which includes access to centralized marketing authorization in the European Union, ten years of protection from market competition with similar medicines in similar indications and fee reductions for regulatory activities. In the US, orphan-drug designation qualifies the sponsor of the drug for various development incentives, including tax credits for qualified clinical testing, waiver of user fees and potentially up to seven years of market exclusivity for the given indication, if approved.

Similar Private Companies By Industry

Company Name Region
4bases S.A. Europe
AB2 Bio Ltd. Europe
ADC Products Switzerland SARL Europe
ADC Therapeutics SA Europe
AlloCyte Pharmaceuticals AG Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
NYC2012, Inc. United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Vaximm AG, please visit www.vaximm.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.